Subclinical myocardial injury in patients with Facioscapulohumeral muscular dystrophy 1 and preserved ejection fraction - assessment by cardiovascular magnetic resonance by Blaszczyk, E. et al.
RESEARCH Open Access
Subclinical myocardial injury in patients
with Facioscapulohumeral muscular
dystrophy 1 and preserved ejection fraction
– assessment by cardiovascular magnetic
resonance
Edyta Blaszczyk1,2, Ulrike Grieben3, Florian von Knobelsdorff-Brenkenhoff1,2,4, Peter Kellman5, Luisa Schmacht1,2,
Stephanie Funk1,2, Simone Spuler3 and Jeanette Schulz-Menger1,2*
Abstract
Background: Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is an autosomal dominant and the third
most common inherited muscle disease. Cardiac involvement is currently described in several muscular dystrophies
(MD), but there are conflicting reports in FSHD1. Mostly, FSHD1 is recognized as MD with infrequent cardiac
involvement, but sudden cardiac deaths are reported in single cases.
The aim of this study is to investigate whether subclinical cardiac involvement in FSHD1 patients is detectable in
preserved left ventricular systolic function applying cardiovascular magnetic resonance (CMR).
Methods: We prospectively included patients with genetically confirmed FSHD1 (n = 52, 48 ± 15 years) and
compared them with 29 healthy age-matched controls using a 1.5 T CMR scanner. Myocardial tissue differentiation
was performed qualitatively using focal fibrosis imaging (late gadolinium enhancement (LGE)), fat imaging (multi-
echo sequence for fat/water-separation) and parametric T2- and T1-mapping for quantifying inflammation and
diffuse fibrosis. Extracellular volume fraction was calculated. A 12-lead electrocardiogram and 24-h Holter were
performed for the assessment of MD-specific Groh-criteria and arrhythmia.
Results: Focal fibrosis by LGE was present in 13 patients (25%,10 men), fat infiltration in 7 patients (13%,5 men). T2 values
did not differ between FSHD1 and healthy controls. Native T1 mapping revealed significantly higher values in patients
(global native myocardial T1 values basal: FSHD1: 1012 ± 26ms vs. controls: 985 ± 28ms, p < 0.01, medial FSHD1: 994 ± 37
ms vs. controls: 982 ± 28ms, p = 0.028). This was also evident in regions adjacent to focal fibrosis, indicating diffuse
fibrosis. Groh-criteria were positive in 1 patient. In Holter, arrhythmic events were recorded in 10/43 subjects (23%).
Conclusions: Patients with FSHD1 and preserved left ventricular ejection fraction present focal and diffuse myocardial
injury. Longitudinal multi-center trials are needed to define the impact of myocardial changes as well as a relation
between myocardial injury and arrhythmias on long-term prognosis and therapeutic decision-making.
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Background
Facioscapulohumeral muscular dystrophy type 1
(FSHD1) is an autosomal dominant disorder and the
third most common inherited muscle disease with an in-
cidence of 1:8.000–1:20.000 [1]. Diagnosis of FSHD1 is
often suspected in patients with presence of progressive
asymmetric weakness of the face and shoulder muscles.
However, 10–25% of patients are wheelchair-dependent
[2]. Usually females have later onset and slower progres-
sion. This leads to a rate of 20% of misdiagnosed FSHD1
patients. Due to mild or unspecific symptoms females,
as asymptomatic carriers, are often not or identified late
[3]. The molecular test used for FSHD1 diagnosis is pri-
marily based on the initial observation, that 95% of
FSHD1 patients carry a reduction of integral numbers of
D4Z4 repeats at 4q35 of the subtelomeric region of
chromosome 4 [4].
Cardiac involvement in patients with other neuromus-
cular diseases (NMD) is more common. It may occur in
up to 90% of patients in the general muscular dystrophy
(MD) population, leading to heart failure and sudden
cardiac death (SCD) [5]. Arrhythmias, as well as myocar-
dial fibrosis, cause earlier clinical impairment in NMD
than in other cardiomyopathies [6]. Recently, focal fat as
well as focal and diffuse myocardial fibrosis could be de-
tected in patients with myotonic dystrophy type 2
(DM2) and preserved left ventricular (LV) ejection frac-
tion (LVEF) applying cardiovascular magnetic resonance
(CMR) [7].
FSHD1 is usually recognized as a NMD with infre-
quent myocardial involvement, but SCD and progressive
heart failure are reported [8]. Furthermore, Trevisan et
al. reported arrhythmic events in 12% of the
FSHD1-patients [9]. The lack of data is also reflected in
the current American Academy of Neurology FSHD
Guidelines [2]. The aim of this study is to investigate
whether subclinical cardiac involvement in FSHD1 pa-
tients is detectable in still preserved LV systolic function
applying CMR.
Methods
Study population
The study was approved by the local ethic committee
(EA1/169/15) and all subjects gave written informed
consent.
We prospectively screened 64 patients with FSHD1 of
which 58 patients could be included in the study. CMR
could not be completely performed in 6 patients: 3 due to
arrhythmia (2 patients were excluded due to ventricular bi-
geminy and one patient due to atrial fibrillation), 1 claustro-
phobia, 1 obesity, 1 known allergy to contrast media.
Finally, 52 patients (age 48 ± 15y, 36 men) were analyzed.
The diagnosis of FSHD1 was defined as partial loss of
D4Z4 macrosatellite repeats units in the subtelomeric
region of chromosome 4. While patients with FSHD1
present 1–10 repeats, there are 11–110 repeats in the
general population [4]. Exclusion criteria were
pre-existing cardiovascular diseases, malignancies or
contraindication for CMR.
Patients underwent a cardiological work-up including
physical examination and echocardiography to confirm a
preserved LVEF. A LVEF lower than 55% was defined as
an exclusion criterion [10].
A detailed patient medical history was recorded. Labora-
tory hematocrit was assessed just before CMR for quanti-
fication of extracellular volume fraction (ECV). Blood
pressure was taken before and after CMR. Assessment of
heart rhythm abnormalities was based on a 12-lead elec-
trocardiogram (ECG) and an ambulatory electrocardiog-
raphy monitoring for 24 h (Holter-ECG). Patients were
also considered at risk of sudden death according to the
Groh-criteria [11]. Following the criteria, patients were
ranked positive if one of the following criteria was given:
no sinus rhythm, PR interval ≥ 240ms, QRS duration≥120
ms, second- or third-degree atrioventricular block.
Screening for conduction abnormalities and arrhythmias
was performed using a Holter. Low atrial rhythm is de-
fined as inverted P waves in lead II, III, and aVF.
The group of patients was compared to 29 healthy sub-
jects. The healthy population has been previously published
[7, 12]. They underwent CMR and ECG. The protocol was
exactly the same for both groups. Exclusion criteria were
similar to the patient group. Details are given in Table 1.
Cardiovascular magnetic resonance
CMR protocol
We applied CMR on a 1.5 T CMR Scanner (MAGNE-
TOM AvantoFit®, Siemens Healthineers, Erlangen,
Germany) using a 32-channel surface coil. The scan
protocol, as recently published [7], is given in Fig. 1. Cine
imaging was performed applying a balanced steady state
precession sequence (bSSFP) to determine the global car-
diac performance. We acquired a four (4Ch), three (3Ch)
and two (2Ch) chamber view (echo time (TE) 1.2 ms;
repetition time (TR), 35ms; voxel size 1.8 × 1.8 × 6.0mm3)
as well as a short axis (SAX) package (TE 1.1ms;
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repetition time, 63ms; voxel size 2.0 × 1.4 × 7.0mm3) to
cover the LV. Short axis stacks were planned and acquired
always in the same ways.
For myocardial tissue differentiation, parametric T1-
and T2-mapping, fat/water-separated imaging and focal fi-
brosis imaging (late gadolinium enhancement, LGE) were
acquired. T2- and T1-mapping were performed in basal,
medial and apical slices as described recently [7, 12].
In short, motion-corrected T2-mapping was based on
bSSFP gradient echo techniques (three single-shot im-
ages with T2 evolution values of 0/24/55 ms, slice thick-
ness 6 mm) [13].
Motion-corrected T1-mapping, based on modified
look-locker inversion-recovery (MOLLI) [14], was performed
to detect diffuse fibrosis. A sampling protocol with reduced
sensitivity to heart rate was applied [15] before and 15min
after contrast media (0.15mmol/kg body weight Gadoteriol)
application (T1 native: 5 s(3 s)3 s; T1 post-contrast: 4 s(1 s)3
s(1 s)2 s; TE 1.1ms and slice thickness 6mm).
A multi-echo sequence was used for fat/water-se-
paration [16] to detect myocardial fat deposits in
4CV and five short axis. Slice position was similar to
the T1 and T2 maps. Gradient echo sequence (GRE),
double inversion recovery dark blood preparation,
four echoes with monopolar readout, TR 450 ms, TE
1.6 ms, sth 6 mm.
Fig. 1 Scan protocol. LV = left ventricle; LAX = long axis; SAX = short axis; 4Ch = four chamber view; SSFP = steady state free precession; MOLLI =
modified look-locker inversion-recovery; CMR = cardiovascular magnetic resonance
Table 1 Patient characteristic. BP = blood pressure; HR = heart
rate; BMI = body mass index; MI = myocardial infarction; * p <
0.05 (healthy compare to FSHD)
All FSHD1
patients
(n = 52)
Healthy
subjects
(n = 29)
FSHD1 with
focal fibrosis
(n = 13)
FSHD1 without
focal fibrosis
(n = 39)
General characteristics
Age (years) 48 ± 15 44 ± 14 55 ± 14 46 ± 14
HR/min 75 ± 12 74 ± 10 73 ± 10 75 ± 13
Systolic BP
(mmHg)
131 ± 7 130 ±
20
133 ± 6 130 ± 8
Diastolic BP
(mmHg)
79 ± 8 76 ± 9 82 ± 8 78 ± 9
BMI (kg/m2) 25 ± 5 24 ± 3 27 ± 3 * 24 ± 5
Further characteristics
Hypertension (%) 21.2 None 46.2 12.8
Type 2 diabetes
mellitus (%)
1.9 None None 2.6
Smoker (%) 7.7 14.8 23.1 2.6
History of MI (%) None None None None
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Focal fibrosis imaging using LGE was performed in the
same slice position as the cine imaging in 4CV, 3CV, 2CV
and short axis (gradient echo sequence, breath-held seg-
mented protocol with 10ms echo spacing, TE of 5.2ms,
and slice thickness of 7mm) 10–15min after administra-
tion of contrast media. The protocol for the healthy control
group was similar.
Data analysis
Image analysis was performed using cvi42 version 5.3.2
(Circle Cardiovascular Imaging, Calgary, Canada).
Short axis cine images were used to determine LV vol-
umes, mass and function by drawing endo- and epicar-
dial contours (papillary muscles as part of the mass) at
the end of the systolic and diastolic phases [17].
Both, the values of T2 and T1 maps were quantified as
previously reported [7]. The qualitative survey implied the
exclusion of segments in case of artifacts (e.g., caused by
susceptibility effects or unintended thoracic motion) or
wrong motion correction as described recently [7, 12]. In
addition, we calculated the ECV by means of native and
post-contrast T1 values and the hematocrit as published
[18]. The hematocrit was assessed just before CMR, when
the patient was already in the scanner (about 5min before
scan was started).
The quantitative analysis of mapping was performed as
average value for slice and for each segment separately. The
ROI was defined by the delineation of the endocardial and
epicardial border of the myocardium. To ensure that blood
or extramyocardial tissue are not included, safety rim of 5%
was used. The segments were defined following the Ameri-
can Heart Association (AHA) segment model [19]. The vis-
ual evaluation of the LGE images was performed by two
independent, experienced readers (SCMR Level III) to as-
sess the presence, number and location of focal scar.
The detection of tiny fatty spots was possible applying
fat/water separated imaging. Imaging was analyzed using
pre-defined criteria [20]. A suspected region was consid-
ered positive if the intramyocardial fat could be either
assured coexistent in the fat-separated image (hyperin-
tense) and in the water-separated image (hypointense)
or detected in one of the separated images and in the
cine images and the LGE. That approach was verified by
two experienced readers as recently published [7].
Statistical analysis
All results are shown as mean ± standard deviation. The
statistical analysis was performed using SPSS® Statistics
23 (International Business Machines Corp., Armonk,
New York, USA). Normal distribution was analyzed
graphically and with Kolmogorov-Smirnov test. For the
comparisons of healthy volunteers to patients as well as
within the FSHD1 group, we used an unpaired t-test and
Mann–Whitney U test, respectively. A p value < 0.05
was considered to indicate a statistically significant dif-
ference. Correlation analyses were performed using the
Spearman rank correlation coefficients. For intra- and
interobserver reproducibility. Images were analyzed
twice by blinded readers.
Results
CMR analysis
LV chamber quantification
No significant differences were found between patients
and healthy subjects in LVEF (p = 0.253), LV mass Index
(p = 0.211) as well as LV end-diastolic volume index
(LVEDVi) (p = 0.192). (Table 2).
Myocardial tissue differentiation
Focal fibrosis
In the FSHD1 group, focal fibrosis was present in 13/52
patients (25%, 10 men). The three most frequent loca-
tions were the basal segments: inferolateral (Fig. 2), in-
ferior and in the interventricular septum (Fig. 3). Only
in one male patient the extension was larger and reached
the mid-ventricular region. The pattern of the fibrosis
was non-ischemic and mostly located intramural (10 pa-
tients, 77%), in 3 (23%) also subepicardial. Healthy sub-
jects did not show focal fibrosis. Both readers had
similar results.
There was no difference between LGE-positive and
LGE-negative patients with regard to age (55 ± 14 vs. 46
± 14 years, p = 0.063), LVEF (62 ± 4% vs. 63 ± 5%, p =
0.626) or LVEDVi (0.69 ± 0.13 ml/cm vs. 0.69 ± 0.09 ml/
cm p = 0.991) (Tables 1 and 2).
Focal fat
Focal fat infiltration was observed in 7/52 patients (13%,
5 men), always located in the apical part of the interven-
tricular septal wall (Fig. 4), whereas focal fibrosis was
never shown in this region. None of the healthy subjects
Table 2 Left ventricle characteristic
All FSHD1
patients
(n = 52)
Healthy
subjects
(n = 29)
FSHD1 with
focal fibrosis
(n = 13)
FSHD1 without
focal fibrosis
(n = 39)
EF (%) 63 ± 5 64 ± 4 62 ± 4 63 ± 5
EDV (mL) 126 ± 21 120 ± 22 127 ± 29 125 ± 17
ESV (mL) 48 ± 11 43 ± 11 50 ± 13 48 ± 11
SV (mL) 78 ± 15 77 ± 13 77 ± 20 78 ± 12
EDVi (mL/cm) 0.69 ± 0.10 0.73 ± 0.13 0.69 ± 0.13 0.69 ± 0.09
LVMi (g/cm) 0.55 ± 0.12 0.58 ± 0.08 0.61 ± 0.13* 0.53 ± 0.11
EF = ejection fraction; EDV = end-diastolic volume; ESV = end-systolic volume;
SV = stroke volume; EDVi = end-diastolic volume index; LVMi = left ventricular
mass index. * p < 0.05 (healthy subjects compared to FSHD1)
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presented fat infiltration. Three FSHD1 patients had evi-
dence of both focal fibrosis and fat infiltration.
Parametric mapping
The medial and basal slices were analyzed. Reliability
was high for both inter- and intra-observer evaluations
(r = 0.93 and 0.94, ICC = 0.82 and 0.92). Apical segments
were excluded due to the high exclusion rate (in 62% ar-
tifacts and/or inaccurate motion-correction).
T2-mapping
Basal and medial T2 maps of 52 patients were evaluated.
6/624 segments had to be excluded due to artifacts. T2
values did not differ between FSHD1 patients and the
control group (basal: FSHD1 50.0 ± 3.5 ms vs. controls
49.5 ± 2.2 ms, p = 0.159; medial: FSHD1 51.0 ± 2.8 ms vs.
controls 49.8 ± 2.4 ms, p = 0.108).
T2 values did not differ between LGE-positive and
LGE-negative FSHD1 patients (basal: LGE(+) 50.1 ± 2.2
ms vs. LGE(−) 50.0 ± 3.9ms, p = 0.932; medial: LGE(+)
50.4. ± 3.1ms vs. LGE(−) 51.2 ± 2.8ms, p = 0.391). There
were also no gender differences within the FSHD1 group
(basal: FSHD1 men:49.7 ± 3.7 vs. women:50.7 ± 2.9 ms,
p = 0.058; medial: FSHD1 men:50.4 ± 2.6 vs. women:52.0
± 2.7ms, p = 0.054).
Native T1-mapping and ECV
Basal and medial native T1 maps of 52 patients were
evaluated. 56/624 segments had to be excluded due
to artifacts and incorrect motion correction. Global
native myocardial T1 values were significantly longer
in FSHD1 patients compared to healthy subjects, both
in the basal (FSHD1:1012 ± 26 ms vs. healthy:985 ± 28
ms, p < 0.01) and the medial slices (FSHD1:994 ± 37
vs. controls:982 ± 28 ms, p = 0.028). Compared to
healthy subjects, native myocardial T1 values were
longer in segments with focal fibrosis (basal inferolat-
eral: p < 0.01, basal inferior: p = 0.033, basal antero-
septal: p < 0.01). Interestingly, Native myocardial T1
values were also increased within the adjacent medial
segments (inferolateral: p = 0.032, inferior: p = 0.041,
anteroseptal: p < 0.01) (Fig. 5). The same could be ob-
served for ECV. ECV of the basal and medial slices
was higher in patients than healthy subjects (basal:
FSHD1: 26.3 ± 2.9% vs. healthy: 23.7 ± 2.2%, p < 0.01,
medial: FSHD1:26.4 ± 3.1% vs. controls:24.2 ± 2.4%, p
Fig. 3 4-chamber view of an FSHD1 patient. Myocardial fibrosis in the septal wall (left) and increased T1-values (1115ms) (right)
Fig. 2 Focal myocardial fibrosis in a FSHD1 patient detected by late gadolinium enhancement (LGE) imaging. Basal inferolateral fibrosis (arrows)
with non-ischemic pattern in (left) three-chamber-view and (right) short axis slice
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< 0.01). ECV was higher not only in segments with
focal fibrosis (basal inferolateral: p < 0.01, basal infer-
ior: p < 0.01, basal anteroseptal: p < 0.01, basal infero-
septal: p = 0.027), but also within the adjacent regions
(medial inferolateral: p = 0.048, medial inferior: p =
0.021, medial anteroseptal: p < 0.01, medial inferosep-
tal: p = 0.024) (Fig. 6).
Sex and gender differences
Healthy women and healthy men
There was no difference in global native T1 in the
healthy control group between men and women. Native
T1 in the basal slice: 978 ± 35 vs. 992 ± 18 ms (p =
0.275). Medial: 979 ± 33 vs. 985 ± 23 ms, (p = 0.394).
Global ECV was also similar: Basal (men: 23 ± 2.1% vs.
women:25 ± 3.2% (p = 0.519)) and medial (men:24 ± 2%
vs. women:25 ± 3.8% (p = 0.866)).
FSHD1 men and FSHD1 women versus healthy controls
We compared all healthy subjects with FSHD1 men
and FSHD1 women separately. In male patients, T1
native and ECV values were only significantly higher
in segments with focal fibrosis. In female FSHD1 pa-
tients, T1 native and ECV values were also signifi-
cantly higher in other regions. Details are given in
Figs. 7 and 8.
Fig. 5 Assessment of myocardial fibrosis- Comparison of all patients with FSHD1 and healthy subjects AHA segments showing native T1 values in
ms. Significant differences between healthy controls and patients were found not only in LGE-positive segments (basal inferolateral: p < 0.01,
basal inferior: p = 0.033, basal anteroseptal: p < 0.01), but also within the adjacent regions (medial inferolateral: p = 0.032, medial inferior: p = 0.041,
medial anteroseptal: p < 0.01)
Fig. 4 4-chamber view showing fat/water separated imaging in a patient with FSHD1. Fat accumulation detected in the apical part of the
interventricular septum (red circles) presented hyperintense in the fat-separated (left) and hypointens in the water-separated image (right)
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FSHD1 women versus FSHD1 men
The subtle effect of sex remained significant within the
FSHD1 patient group. To avoid the impact of focal fi-
brosis on the results, we excluded basal segments (the
most common localization of focal fibrosis) from our
calculations and compared T1 values and ECV in the
medial slice. Both, the medial T1 values (FSHD1 men:
992 ± 26 vs. women: 998 ± 54ms, p = 0.047) and the
medial ECV (FSHD1 men: 26 ± 3 vs. women: 28 ± 3ms,
p = 0.041) were slightly increased in females.
Heart rhythm abnormalities
Interpretable ECGs were available in 45 patients (88%),
Holter in 43 (83%). Holter was not available in 3/17 pa-
tients with focal myocardial injury. Arrhythmic events
were recorded in 10/43 (23%) FSHD1 patients.
Fig. 6 Assessment of myocardial fibrosis- Comparison of all patients with FSHD1 and healthy subjects with AHA segments showing ECV values in
%. Significant differences between healthy suybjects and FSHD1 patients were found not only in LGE-positive segments (basal inferolateral: p <
0.01, basal inferior: p < 0.01, basal anteroseptal: p < 0.01, basal inferoseptal: p = 0.027), but also within the adjacent regions (medial inferolateral:
p = 0.048, medial inferior: p = 0.021, medial anteroseptal: p < 0.01, medial inferoseptal: p = 0.024)
Fig. 7 Sex differences regarding native T1 values in ms between FSHD1 patients and healthy subjects
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Non-sustained ventricular tachycardia was detected in
one patient (9 monomorphic QRS complexes, 140 bpm),
premature ventricular beats > 1000 in 3/43, runs of sup-
raventricular tachycardia (SVT) in 4/43 (124/130/140/
163 bpm increasingly, the longest 146 s) and intermittent
low atrial rhythm in three patients. Ventricular arrhyth-
mias were detectable in 4/7 patients (57%) with fat de-
posits and in 1/13 with focal fibrosis. SVT was evident
in one patient with fat deposits and in one with focal fi-
brosis. The patient with non-sustained ventricular tachy-
cardia had evidence of focal fibrosis and fat infiltration.
There was only one patient with positive Groh-criteria
(low atrial rhythm) and normal CMR. T wave abnormal-
ities could not be identified in any patient.
Discussion
In our FSHD1 population with preserved LVEF, we
found myocardial tissue changes such as, focal fibrosis/
LGE in 25% and focal fat infiltration in 13%. Diffuse sub-
clinical fibrosis was detectable in segments adjacent to
focal fibrosis probably indicating an ongoing process. Fe-
males seem to have slightly more diffused myocardial
changes. Age was not different in patients with and
without fibrosis. Heart rhythm abnormalities were de-
tected also in patients with myocardial injury.
Although we had excluded all patients with impaired
LV systolic function, cardiac involvement in FSHD1 can
be detected. Our findings support the case reports [8, 9,
21] describing cardiac events in this disease. To the best
of our knowledge, this is the first clinical study showing
the presence of myocardial changes in patients with
FSHD1 with preserved LVEF in vivo.
Focal fibrosis was predominantly located in the inferolat-
eral region. This localization is not pathognomonic for
NMD as it is also described in other cardiac diseases such as
inflammatory disease, mitochondrial myopathy, MD 2 or Eo-
sinophilic Granulomatosis with Polyangiitis [7, 22–24]. Focal
myocardial fat infiltration in MD was already described in
case reports, but not systematically studied. Schmacht at al.
showed that fat deposits are detectable in 21% of patients
with DM2, interestingly only in female [7, 25].
Cardiac involvement in MD is well recognized in Du-
chenne muscle dystrophy (DMD) and Becker muscle
dystrophy (BMD) and other muscular dystrophies with
lamin A or C mutations. They are often associated with
dilated cardiomyopathy and ventricular arrhythmias
[26–28]. Arrhythmias and heart failure are responsible
for the high mortality. This underlines the impact of an
early diagnosis, as shown by Yilmaz et al. using CMR
[23]. Recently, we could show that in DM2 myocardial
injury is detectable already in preserved LVEF [7].
Whereas the occurrence of arrhythmias and conduc-
tion abnormalities is well known in the case of dilated
cardiomyopathy [29], the association of arrhythmias and
myocardial injury in patients with still preserved systolic
LV-function remains unknown.
Patients with different types of MD are known to suf-
fer from supraventricular- and ventricular arrhythmias
as well as high-degree conduction disturbances like
atrioventricular blocks [30]. Asymptomatic patients with
myotonic dystrophy type 1 presenting the Groh-criteria
were at higher risk of sudden death compared to those
with normal ECGs [11]. Currently, the implication for
potential device treatments in patients with MD, like the
early implantation of a cardioverter-defibrillator (ICD)
or a pacemaker (PM), is not obvious. The European So-
ciety of Cardiology Guidelines indicates that in this pa-
tient group the devices should be considered earlier than
Fig. 8 Sex differences regarding ECV in % between FSHD1 patients and healthy subjects
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in other cardiac disorders [31]. Nevertheless, due to
young age and clinical presentation in that population,
the decision is often difficult. Additional information
about myocardial tissue changes could be helpful to
guide therapeutically decision making in some cases.
Myocardial fat infiltration is less studied, but due to
recent technical developments the identification of small
changes is less challenging [16, 20]. Pouliopoulos et al.
published that fatty metaplasia in myocardial infarction
is related to arrhythmia [32]. Furthermore, Lu at al. re-
ported common prevalence of myocardial fat in dilated
cardiomyopathy (DCM) patients and its significant rela-
tion to LV global function as well as possible influence
on the prognosis of DCM [33]. The results of a FSHD
multicenter study indicate the susceptibility to supraven-
tricular arrhythmia as a possible feature of FSHD [9]. In
our study we have registered ventricular arrhythmias in
a few patients, however due to the relatively small num-
ber of participants there was no statistically significant
relation between focal myocardial changes and heart
rhythm disturbances. The registered rhythm distur-
bances do not show evidence of an increased risk of sud-
den cardiac death. Further studies in larger series of
patients have to be performed to investigate potential re-
lation between arrhythmias and myocardial injury in
FSHD1 patients.
Parametric mapping is an innovative and reproducible
method and brings unique quantitative diagnostic infor-
mation about the myocardium. In the future, it may
allow avoidance of contrast-media. In our study focal fi-
brosis as well as adjacent subtle diffuse fibrosis were de-
tectable in a quarter of patients, using parametric
mapping. Interestingly, we were able to identify differ-
ences between patients and healthy controls, but the ab-
solute values in patients were still within the normal
range. Our findings are underlining two aspects, first –
quantitative mapping needs standardization and second
it offers the chance to detect myocardial injury in a very
early stage. Similar to our findings, Florian et al. showed
in patients with different types of MD that ECV was able
to detect subtle diffuse fibrosis in myocardial areas with-
out focal fibrosis [34]. Similar to our study, CMR identi-
fied diffuse myocardial changes in DMD without the
presence of focal fibrosis [35].
Sex and gender differences in different cardiac diseases
are well known [36]. It has also been proven that sex has
a significant influence on the development of auto-
immune diseases as well as on the regulation of fibrosis
and inflammation in LV muscle remodeling [37, 38]. In
different MD sex and gender differences are related to
cardiac manifestations, progression and outcome [39].
While female carriers of DMD rarely present clinical
symptoms, cardiac involvement may develop in up to
50% of cases. In contrast to DMD males, female carriers
may not clinically develop peripheral muscular disease
but can present a wide range of cardiac incidents includ-
ing heart failure and SCD [40].
In our study we could detect subtle sex and gender re-
lated differences in myocardial structure in FSHD1 pa-
tients compared to healthy subjects. These findings need
further evaluation and confirmation. Interestingly, similar
findings are described in other secondary cardiomyopa-
thies. Cocker et al. identified in patients with viral myocar-
ditis that males had a higher incidence of focal fibrosis,
while women showed more often diffuse injury [41]. The
potential impact of the significant, but small differences in
T1-mapping will be a matter of further research.
Although cardiac abnormalities in FSHD1 patients are
less recognized than in other MD, autopsy data reported
myocardial fibrosis and focal fatty infiltrations. CMR al-
lows the detection of myocardial tissue damage such as
different types of fibrosis and fat already in the absence
of functional abnormalities. Our findings in FSHD1 pa-
tients with preserved LVEF have to be elucidated in
long-term follow-up studies. But it adds knowledge re-
garding the capability of CMR to detect myocardial in-
jury in preserved LVEF.
Limitations
This is a single center cross-sectional study and the sam-
ple size of the matched groups is relatively small, but all
of the subjects have a genetically confirmed diagnosis
and all patients are well characterized in our department
of neurology. In the view of the prevalence of the dis-
ease, it should be considered as representative.
ECG as well as Holter-ECG was not available in all pa-
tients due to hyperaesthesia or logistic patient related
reasons. Patients with arrhythmias that could influence
the CMR scan quality were excluded from the study.
The potential impact of the significant, but small dif-
ferences in T1-mapping related values have to be eluci-
dated in further long-term follow-up trials.
We could not identify a relation between arrhythmia
and native T1 mapping. But we have investigated only
patients with preserved LVEF. One could expect that a
larger sample size and an inclusion of all FSHD1 pa-
tients would lead to different results.
The capability of prolonged monitoring and inclusion
of all FSHD1 patients to influence clinical outcomes
should be evaluated in following studies.
Conclusions
Patients with FSHD1 and preserved LVEF show focal and
diffuse myocardial injury. FSHD1 men have more often
focal fibrosis, while in females diffuse myocardial changes
seem to be more common. Myocardial fat infiltration is
detectable as well. Further longitudinal multi-center trials
are needed to investigate a potential relation between
Blaszczyk et al. Journal of Cardiovascular Magnetic Resonance           (2019) 21:25 Page 9 of 11
heart rhythm abnormalities and myocardial injury and its
impact on long-term prognosis in FSHD1.
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